Nā ʻikepili hou o ka maʻi maʻi maʻi maʻi maʻi maʻi no nā ʻōpū paʻa

Ua hoʻolaha ʻo Nouscom i kēia lā i ka paipai ʻana i ka ʻikepili unuhi hou i loaʻa mai ka hoʻāʻo ʻana o ka Phase 1 e loiloi ana i ka NOUS-209. Ua hōʻike ʻia ka ʻikepili i nehinei i kahi hālāwai Late Breaking ma ka 2022 American Association for Cancer Research (AACR) Annual Meeting.

ʻO NOUS-209, ka huahana alakaʻi a Nouscom, he maʻi maʻi maʻi maʻi ma waho o ka papa e kuhikuhi ana i 209 mau neoantigens. Ke noiʻi ʻia nei i loko o kahi hoʻokolohua lapaʻau Phase 1, lawelawe ʻia me ka anti-PD-1 checkpoint inhibitor pembrolizumab, no ka mālama ʻana i ka Microsatellite Intable High (MSI-H) gastric, colorectal a me gastro-esophageal junction solid tumors.

Ua hōʻike mua ʻia ka ʻikepili lapaʻau interim o ka hui ʻana (i hōʻike ʻia ma ka Society for Immunotherapy of Cancer's (SITC) Annual Meeting i Nowemapa 2021) i hōʻike ʻia i nā hōʻailona mua o ka pono lapaʻau i nā maʻi maʻi 12 MSI-H.

Ua kākoʻo hou ka ʻikepili unuhi hou i hōʻike ʻia ma AACR 2022 i kēia mau ʻike a hōʻike ʻia ʻo NOUS-209 he palekana, immunogenic nui me nā hōʻailona hoʻohiki o ka pono lapaʻau. ʻO nā mea nui i ʻike ʻia penei:

• Ua hōʻike ʻia ka maʻi immunogenicity e ka ex-vivo IFN-ɣ ELISpot assay i 67% o nā mea maʻi i ka pae pae 1 (n=3), a me 100% (n=7) o nā maʻi i ka pae pae 2.

• I loko o 3 mau maʻi me nā PR wā lōʻihi i loaʻa nā biopsies tumo ma mua / ma hope o ka mālama ʻana, ua hoʻonui ʻia ka repertoire TCR intratumoral a ua hoʻololi ʻia ka mālama ʻana me NOUS-209. Hoʻonui ʻia ka hoʻomanaʻo T effector ma hope o ka mālama ʻana.

• I loko o kekahi o kēia mau maʻi ʻekolu, ʻike ʻia ka TCR kikoʻī neoantigen i hoʻokomo ʻia i ka maʻi mai ka ʻaoʻao o ka biopsy tumo ma hope o ka mālama ʻana NOUS-209.

• Hōʻike nā hualoaʻa i ka neoantigen kikoʻī CD8 + T cell, i hoʻoulu ʻia e NOUS-209, hoʻonui a hoʻololi wale i ka mālama ʻana me NOUS-209, a hoʻokomo maikaʻi i ka microenvironment tumor e hoʻoikaika i ka hana anti-tumor.

Ua ʻōlelo ʻo Marwan G. Fakih, MD, Medical Oncology Specialist ma City of Hope's Duarte California, a me Study investigator: "ʻOiai ua ʻike mākou i ka holomua o nā koho lapaʻau no nā maʻi maʻi paʻa MSI-High i nā makahiki i hala iho nei, aia nō kahi hemahema nui ʻole. No laila he mea hoʻoikaika nui ka ʻike ʻana i kēia ʻikepili unuhi hou ʻo Phase 1 e hōʻike ana i ke ʻano o ka NOUS-209 e hoʻoulu ai i ka hoʻonui ʻana o T cell a me TCR diversification i nā maʻi e hōʻike ana i nā pane lapaʻau lōʻihi. Manaʻo nui wau i ka nānā piha ʻana i nā hopena o ka Phase 1 a me ka hoʻomohala hou aʻe.

Ua ʻōlelo ʻo Dr. Elisa Scarselli, Luna Nui ʻepekema a me Co-Founder o Nouscom: "ʻO ka ʻikepili, i loaʻa mai 12 mau mea maʻi MSI-H metastatic, e hōʻike ana i kahi pūlima maʻamau i ʻike ʻia ma hope o ka hoʻopaʻa ʻana i nā maʻi me ka pane lapaʻau lōʻihi. Hōʻike ʻia ka pūlima e ka TCR repertoire hoʻonui a me ka hoʻololi ʻana i nā lymphocytes infiltrating tumor i hoʻoulu ʻia e ka hoʻopaʻa ʻana me NOUS-209, me ka hoʻonui like ʻana o nā cell T me ka phenotype memory effector. Eia kekahi, ua hiki iā mākou ke hahai i nā pūnaewele T i hoʻokomo ʻia i ka maʻi ma waena o nā mea i hoʻonui ʻia ma hope o ka mālama ʻana i ka ʻōpū o kekahi o kēia mau maʻi.

"Ke kakali nei mākou i ka kūkulu ʻana ma luna o kā mākou ʻikepili hōʻoia-o-manaʻo ma o ka hoʻohana ʻana i nā aʻo koʻikoʻi mai ka hoʻāʻo ʻana e kākoʻo i ka hoʻomohala ʻana o NOUS-209 ma ke ʻano he neoantigen mua loa o ka maʻi maʻi maʻi maʻi maʻi e kuhikuhi ana i nā ʻōpū MSI-H."